SOPHIRIS BIO INC.
SOPHIRIS BIO INC. (SPHS): 1 pipeline candidate · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.1 months
D/E -3.57 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for SOPHIRIS BIO INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$4.3M
Quarterly Burn
$2.7M
Runway
7.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| topsalysin | Phase 3 |
Frequently asked questions
How many drug candidates are in SOPHIRIS BIO INC.'s pipeline?
SOPHIRIS BIO INC. (SPHS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is SOPHIRIS BIO INC.'s lead drug candidate?
SOPHIRIS BIO INC.'s most advanced tracked candidate is topsalysin (Phase 3) for intermediate risk localized prostate cancer.
What is SOPHIRIS BIO INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SOPHIRIS BIO INC. has approximately 7.1 months of cash runway.
Who is the CEO of SOPHIRIS BIO INC.?
Randall E. Woods is the chief executive officer of SOPHIRIS BIO INC. (SPHS).
Get the full picture on SOPHIRIS BIO INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.